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Abstract
Introduction In chronic inflammatory disorders, B cells can
contribute to tissue damage by autoantibody production and
antigen presentation to T cells. Here, we have characterized
synovial fluid and tissue B-cell subsets in patients with
oligoarticular juvenile idiopathic arthritis (JIA), an issue not
addressed before in detail.
Methods B cells from synovial fluid (SF) and peripheral blood
(PB) of 25 JIA patients, as well as from PB of 20 controls of
comparable age, were characterized by multicolor flow
cytometry. Immunoglobulin-secreting cells were detected by
ELISPOT. Immunohistochemical analyses of synovial tissue
from three JIA patients were performed.
Results JIA SF B cells were enriched in CD27+ and CD27-
switch memory B cells, but not in CD27+ IgM memory B cells,
compared with patient and control PB. Plasma blasts were more
abundant in SF and secreted higher amounts of IgG. Lymphoid
aggregates not organized in follicle-like structures were
detected in synovial tissue sections and were surrounded by
CD138+  plasma cells. Finally, transitional B cells were
significantly increased in JIA PB versus SF or control PB. CCR5,
CCR8, CXCR2, and CXCR3 were upregulated, whereas
CCR6, CCR7, and CXCR5 were downregulated on SF CD27+
and CD27-  switch memory B cells compared with their
circulating counterparts. SF CD27+ and CD27- switch memory
B cells expressed at high levels the costimulatory molecule
CD86 and the activation marker CD69.
Conclusions This study demonstrates for the first time an
expansion of activated switch memory B cells and of IgG-
secreting plasma blasts in the SF from oligoarticular JIA
patients. Memory B cells belonged to either the CD27+or the
CD27-  subsets and expressed CD86, suggesting their
involvement in antigen presentation to T cells. Patterns of
chemokines-receptor expression on CD27+ and CD27- switch
memory B cells delineated potential mechanisms for their
recruitment to the inflamed joints.
Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous condition
classified into different subtypes according to the symptoms
at onset [1]. Oligoarticular JIA is the most frequent form (26%
to 56% of all JIA) and is characterized by early disease onset,
asymmetric arthritis, high prevalence of iridocyclitis, peculiar
HLA association (HLA-DRB1*1101, DRB1*0801,
DPB1*0201), and the presence of antinuclear antibodies. In
the majority of these patients, the disease remains confined to
a limited number of joints (persistent oligoarticular JIA) and has
a favorable outcome characterized by a high frequency of self-
remission (as reviewed in [2]). Approximately one third of
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patients with oligoarticular onset experience progression
toward a more aggressive form, characterized by the involve-
ment of five or more joints after the first 6 months of disease
(extended oligoarticular JIA). In 10% to 30% of JIA patients,
the disease shows symmetric involvement of more than four
joints, with an erosive course during the first 6 months of dis-
ease (polyarticular-onset JIA). A small proportion of these
patients (3% to 5% of all JIA patients) display positivity for
rheumatoid factor (RF) [2]. The systemic-onset JIA is observed
in 4% to 17% of patients and is characterized by a severe sys-
temic involvement (rash, fever, hepatosplenomegaly) associ-
ated with arthritis of variable severity that may evolve into an
aggressive polyarticular course [2].
A distinctive feature of chronic inflammatory arthritides is the
presence of synovial lymphocytic infiltrates that play a role in
disease pathogenesis through the release of pro-inflammatory
cytokines and other soluble mediators [3-5].
In adult rheumatoid arthritis (RA) and occasionally in JIA [6],
these infiltrates may organize into follicle-like structures,
according to a process known as "ectopic lymphoid neogen-
esis" [3-5]. Both T and B cells are detected in JIA infiltrates [6].
Whereas T cells are likely responding to autoantigens whose
nature has been partially defined [7,8], the pathogenic role of
B cells in JIA is less clear, because the vast majority of patients
test negative for rheumatoid factors [2]. Nonetheless, synovial
lymphocytic infiltrates have been recently correlated with the
presence of serum anti-nuclear IgG antibodies in JIA patients
[6]. The latter observation highlights the relevance of switch
memory B cells in the production of these autoantibodies.
Furthermore, activated switch memory B cells can contribute
to the pathogenesis of JIA by upregulating the expression of
co-stimulatory molecules such as CD80 and CD86 and pre-
senting antigens to T cells [9].
With this background, we here address the immunopheno-
typic and functional characterization of synovial B cells from
JIA patients, with emphasis on switch memory B cells. The
results obtained may be translationally relevant because RA
patients can benefit from treatment with rituxan (Rituximab), a
monoclonal antibody directed to the B cell-specific antigen
CD20 [10,11], and preliminary evidence indicates that the
same treatment may be efficacious in JIA patients [12].
Materials and methods
Patients
This investigation was approved by the Ethical Committee of
the G. Gaslini Institute, Genoa, Italy. All biologic samples
(blood, synovial fluid, or synovial tissue) from juvenile idio-
pathic arthritis (JIA) patients or healthy controls were obtained
with informed consent of the patients' parents or the legal
guardians. JIA individuals were classified according to ILAR
Durban criteria [1]. Twenty-three of 25 patients had oligoartic-
ular JIA, either persistent or extended, and two had RF-polyar-
ticular JIA. All patients were in articular relapse at study. An
intra-articular steroid injection in the previous 6 months was
considered an exclusion criterion. The clinical characteristics
and ongoing treatment are reported in Table 1. The two RF-
polyarticular JIA cases were included in the extended JIA
group for statistical purposes, because of the limited number
of patients studied.
Cell isolation
Mononuclear cells (MNCs) were isolated with Ficoll-Hypaque
density gradients (Sigma Chemical Company, St. Louis, MO)
from synovial fluid (SF) and peripheral blood (PB) of 25
patients with JIA or 20 healthy individuals, comparable with
respect to mean age (no clinical or laboratory evidence for
inflammatory or infectious disorders in the 4 weeks before
testing). MNCs were frozen in a solution containing 10%
dimethyl sulfoxide (Sigma), and stored in liquid nitrogen until
tested. Cells were cultured in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (Sigma).
Flow cytometry
The following monoclonal antibodies (mAbs) were used:
CD19-phycoerythrin(PE)-cyanin(Cy)7, CD38-PerCP/Cy5,
CD27-PerCP/Cy5 from Beckman Coulter (Marseille, France);
CD3-allophycocyanin (APC)-Cy7, CD14-APC-Cy7, CD56-
biotin and CD16-APC-Cy7, streptavidin-APC-Cy7, CD10-PE;
CD24 fluorescein isothiocyanate (FITC), CD20-PE, CD27-
PE, CD27-FITC, CD80-FITC; CD86-PE from BD Pharmingen
(San Diego, CA, USA); CD10-FITC from Biolegend (San
Diego, CA, USA); PE-conjugated anti-human IgD mAb from
Dako (Glostrup, Denmark); anti-human immunoglobulin (Ig)G,
IgA, and IgM-allophycocyanin (APC) from Jackson Immunore-
search Laboratories (West Grove, PA, USA); PE-conjugated
anti-CC chemokine receptor CCR1-CCR9 mAbs from R&D
Systems Inc. (Minneapolis, MN, USA); unconjugated anti-
CXC chemokine receptor CXCR1, CXCR2, and CXCR3
mAbs from Serotec Inc. (Raleigh, NC, USA); and PE-conju-
gated anti-CXCR4 and CXCR5 mAbs from R&D Systems.
Cell staining and flow-cytometric analysis were performed as
reported [13] by using an FACSCanto (Becton-Dickinson).
On average, 104 events were acquired and analyzed by using
the CellQuest software.
The gates and the marker combinations used to analyze B-cell
subpopulations are detailed later. In all flow-cytometry experi-
ments performed in this study, the first step was the exclusion
of non-B cells stained with a combination of the following anti-
bodies and detected in a single channel: CD3, CD14, CD16,
and CD56, all labeled with APC-Cy7.
Naïve B cells were detected as IgD+, IgM+ cells after gating on
CD19+ cells. CD27+ IgM memory B cells were detected as
IgG-, IgA- cells after gating on CD19+ cells and subsequently
on CD27+ cells. CD27+ switch memory B cells were detectedAvailable online http://arthritis-research.com/content/11/5/R150
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as IgG+, IgA+ cells after gating on CD19+ cells and subse-
quently on CD27+ cells. CD27- switch memory B cells were
detected as IgG+, IgA+ cells after gating on CD19+ cells and
subsequently on CD27-  cells. Transitional B cells were
detected as IgM+, IgD+ cells after gating on CD19+ cells and
subsequently on CD24high, CD38high cells. Germinal center-
like B cells were detected as CD10+ cells after gating on
CD19+  cells. Plasma blasts were detected as CD27high,
CD20+/- cells after gating set on CD19+ cells.
Immunohistochemistry
Synovial-membrane samples were obtained from three JIA
patients undergoing synovectomy (two patients) or arthro-
scopic biopsy (one patient). Two independent tissue samples
were collected from each patient, fixed in formalin 10%, and
embedded independently in paraffin blocks or optimal cutting
temperature (OCT) compound, and snap frozen in liquid nitro-
gen-cooled isopentane. Immunohistochemical labeling was
performed with a three-step immunoperoxidase technique.
Formalin-fixed, paraffin-embedded tissue sections were incu-
bated at room temperature for 30 minutes with anti-CD20
mAb (clone L26, DakoCytomation), anti-CD3 polyclonal Ab
(DakoCytomation), anti-CD138 mAb (clone MI15, DakoCyto-
mation), anti-CD19 mAb (clone19C02, Neomarkers), anti-
CD27 mAb (clone137B4, Neomarkers), anti-IgA mAb (clone
6E2C1, DakoCytomation), anti-IgG mAb (clone A57H, Dako-
Cytomation), and anti-IgM mAb (clone R1/69, DakoCytoma-
tion). Sections were subsequently reacted at room
temperature with anti-mouse Ig antibody conjugated to perox-
idase-labeled dextran polymer (DakoCytomation). Chromoge-
Table 1
Clinical and laboratory features of JIA patients enrolled in the study
Patient JIA form Disease duration (years) Number of active joints CRP (mg/dl) ANA Treatment
1 Oligo pers 8 1 1.32 Pos NSAID
2 Oligo pers 6 1 <0.46 Pos ---
3 Oligo pers 2 2 0.83 Pos ---
4 Oligo pers 6 3 0.76 Pos NSAID
5 Oligo pers 8 2 1.85 Pos NSAID
6 Oligo pers 1 2 <0.46 Pos NSAID
7 Oligo pers 5 1 <0.46 Pos ---
8 Oligo pers 10 1 <0.46 Neg ---
9 Oligo pers 6 1 0.61 Pos ---
10 Oligo pers 1 1 <0.46 Pos ---
11 Oligo pers 5 1 <0.46 Pos ---
12 Oligo pers 1 1 <0.46 Pos NSAID
13 Oligo pers 9 1 <0.46 Pos NSAID
14 Oligo ext 6 2 8.3 Pos NSAID, MTX
15 Oligo ext 6 6 6.59 Pos NSAID
16 Oligo ext 3 4 3.5 Pos NSAID, MTX
17 Oligo ext 11 1 <0.46 Pos MTX
18 Oligo ext 10 8 1.25 Pos NSAID
19 Oligo ext 10 4 2.53 Pos CyA, MTX
20 Oligo ext 1 4 0.87 Pos NSAID
21 Oligo ext 2 5 1.34 Pos NSAID
22 Oligo ext 10 1 0.6 Pos MTX
23 Oligo ext 2 1 <0.46 Pos NSAID, MTX
24 Poly RF 5 2 0.87 Pos MTX
25 Poly RF 9 1 0.76 Neg NSAID, adalimumab
Olig pers = oligoarticular persistent; oligo ext = oligoarticular extended; CRP = C-reactive protein (n.v. < 0.46 mg/dl); ANA = antinuclear 
antibody; pos = positive; neg = negative; NSAID = nonsteroidal anti-inflammatory drug = MTX = methotrexate; CyA = cyclosporine A.Arthritis Research & Therapy    Vol 11 No 5    Corcione et al.
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nic diaminobenzidine substrate was applied, and slides
counterstained with Mayer's hematoxylin.
ELISPOT assay
Cells secreting IgG, IgM, or IgA were detected with an ELIS-
POT assay, as reported [13], by using purified goat anti-
human IgG or IgA or IgM from Southern Biotechnology Asso-
ciates (Birmingham, AL, USA). After washing and blocking
with PBS containing 1% BSA for 30 minutes, serial dilutions
of cultured B cells were added and incubated overnight at
37°C. Before plating, cultured B cells were washed 5 times
with complete medium to eliminate the Ig present in the super-
natants. Plates were washed and incubated with isotype-spe-
cific secondary antibodies, followed with streptavidin-HRP
(Sigma). The assay was developed with AEC (Sigma) as the
chromogenic substrate. ELISPOT plates were analyzed blindly
with the bioreader 3000 BIOSYS.
Statistical analysis
Data were reported in terms of medians, minimum and maxi-
mum values, or first and third quartiles. The nonparametric
analysis of variance (Kruskal-Wallis test) was used to compare
quantitative parameters among three groups of observations
(for example, to compare the number of naïve B cells in SF
with respect to PB and to controls' PB); the Dunn test was
used as an a posteriori test. The Mann-Whitney U test was
used to compare quantitative variables between two groups of
observations, and the Bonferroni correction was applied to
avoid multiple comparisons error (PB) (for example, to com-
pare number of CCR5+, CCR6+, CCR7+, CCR8+, and
CCR9+ cells in the SF versus the PB compartment). A P value
less than 0.05 was considered statistically significant. Statisti-
cal analyses were performed by using Graph Pad Prism 3 soft-
ware and the statistical package, Statistica 6 (StatSoft Inc.,
Tulsa, OK, USA).
Results
B-cell subset characterization in synovial fluid from 
oligoarticular JIA patients
We first performed a multicolor flow-cytometric analysis of
MNC isolated from SF and paired PB samples of 25 JIA
patients, as well as from PB samples of 20 age-matched con-
trols. CD19+ cells were less numerous in SF than in paired PB
(SF percentage of positive cells: median, 0.9; range, 0.1 to
3.1; PB percentage of positive cells: median, 12.3; range, 4.6
to 22.0, P  < 0.0001; SF absolute number: median, 24.7;
range, 3.0 to 65.3; and PB absolute number: median, 297.3;
range, 34.8 to 1,067; P < 0.0001). CD19+ cells in control PB
(percentage of positive cells: median, 11.0; range, 4.8 to 28.9;
absolute number median, 283.6; range, 123.7 to 985.1) did
not differ from those in patient PB (see values in parentheses
in the previous sentence).
Naïve (CD19+IgD+CD27-) B cells [14] were less abundant in
SF than in patient and control PB (Dunn test; P  < 0.01),
whereas they were equally represented in control and JIA PB
(Figure 1A). B cells with a germinal center-like phenotype
(CD19+, CD10+ cells) [15] were virtually absent from both SF
andpatient or control PB (data not shown).
The percentage of CD19+CD27+ memory B cells was higher
in SF than in patient PB (SF median, 44.2; range, 10.0 to 73.0;
n = 25; PB median, 16.4; range, 4.1 to 34.9; n = 25; P <
0.0001). No difference was observed between memory B
cells from JIA or control PB (median, 10.5; range, 4.7 to 37.0;
n = 16).
Two subsets of CD19+CD27+ memory B cells have been
identified: (a) IgM memory (CD19+CD27+IgG-IgA-), and (b)
class switch memory (CD19+CD27+IgG+IgA+) B cells
[14,16]. The percentage of IgM memory B cells in SF did not
differ from that in patient PB, which showed values compara-
ble to those in control PB (SF median, 11.0; range, 0.0 to
21.0; n = 25; paired PB median, 8.0; range, 2.4 to 27.6; n =
25; control PB median, 8.2; range, 4.8 to 17.9; n = 16).
CD27+ switch memory B cells were enriched in SF versus
patient PB (Dunn test; P < 0.01) (Figure 1B). The same cell
subset was similarly represented in control and patient PB
(Figure 1B).
Recently, a novel subset of switch memory B cells lacking
CD27 expression (CD19+CD27-IgG+IgA+) was identified
[17-19]. CD27-switch memory B cells were more abundant in
SF than in patient PB (Dunn test; P < 0.01), whereas they
were present in similar proportions in control and patient PB
(Figure 1C).
CD19+CD27-IgG+IgA+ switch memory B cells can be further
subdivided into two subsets according to the expression of
the FcHR4 surface marker [17-19]. SF CD19+CD27-
IgG+IgA+ switch memory B cells tested negative for FcHR4
expression.
CD19+CD24highCD38highIgMhighIgDhigh  transitional B cells
[20] were virtually absent in SF compared with patient and
control PB (Dunn test; P < 0.01) (Figure 2) and were more
abundant in patient than in control PB (Dunn test; P = 0.05)
(Figure 2). It has been reported that transitional B cells can
express CD10 [21]. To address this issue, we stained transi-
tional B cells from patient PB for CD10 and found that the lat-
ter marker was expressed by these cells (15% to 20%; range
from four experiments with different samples) (Figure 2).
Patients with oligoarticular persistent JIA who were receiving
NSAID treatment or were untreated at study did not show sig-
nificant differences in the percentages of all the mentioned B-
cell subsets (naïve B cells, CD27+ and CD27- switch memory
B cells, and plasma blasts), either in SF or in PB. Similar
results were obtained from the comparison of patients with
persistent or extended oligoarticular JIA (not shown).Available online http://arthritis-research.com/content/11/5/R150
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CD19+CD27highCD20+/- plasma blasts [22] were increased in
SF versus patient PB (Dunn test; P < 0.05) (Figure 3A). The
percentage of plasma blasts in control PB and JIA PB was
similar (Figure 3A). The percentage of plasma blasts was
higher in SF from extended than from persistent oligoarticular
JIA patients (P = 0.014).
ELISPOT experiments showed higher numbers of CD19+ IgG-
secreting cells in SF versus patient PB (P = 0.028) (Figure
3B). CD19+ IgA- and IgM-secreting cells were equally repre-
sented in patient SF and PB (Figure 3B). Similar percentages
of IgG-, IgM-, or IgA-secreting B cells were found in patient
and control PB (not shown).
Figure 1
Flow cytometry of B-cell subsets in synovial fluid (SF) and peripheral blood (PB) from juvenile idiopathic arthritis (JIA) patients Flow cytometry of B-cell subsets in synovial fluid (SF) and peripheral blood (PB) from juvenile idiopathic arthritis (JIA) patients.  Mononuclear cells 
(MNCs) from SF and PB of 25 JIA patients, as well as from PB of 20 age-matched controls, were stained with different B cell-specific antibodies 
and analyzed with flow cytometry. The first gate was set on CD3-, CD14-, CD16-, and CD56- cells (non-B cell lineage cells) followed by gating on 
CD19+ cells. Results are expressed in a box plot (left panel) as median percentage of positive cells, minimum and maximum value. * P < 0.01. One 
representative dot-blot for SF (middle panel) and PB (right panel) is shown.Arthritis Research & Therapy    Vol 11 No 5    Corcione et al.
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Immunohistochemical staining for IgG, IgA, and IgM in synovial
tissue sections showed a predominance of IgG-secreting
cells. Lower proportions of IgA- and IgM-secreting cells were
also detected (Figure 3C).
Chemokine receptor and costimulatory molecule expression in
CD27+ and CD27- switch memory B cells from synovial fluid
of oligoarticular JIA patients Next, CD27+ and CD27- switch
memory B cells were characterized with flow cytometry for the
expression of CC chemokine receptors (R) (CCR1-CCR9)
and CXCR (CXCR1-CXCR5), as well as for the CD80 and
CD86 costimulatory molecules.
CD27+ switch memory B cells
CCR5+, CCR8+, and CCR9+  cells were significantly
increased, whereas CCR6+ and CCR7+ cells were decreased
in SF versus patient PB (Figure 4A and Table 2). CXCR1+,
CXCR2+, and CXCR3+ cells were significantly more abun-
dant, whereas CXCR5+ cells were less numerous in SF than
in patient PB cells (Figure 4B and Table 2). No difference in
CXCR4 expression was observed between SF and patient PB
cells.
Finally, CCR and CXCR expression was similar in patient and
control PB cells (not shown). SF cells expressed higher levels
of the CD86 costimulatory molecule than did patient PB cells
(P = 0.0001) (Figure 4B). In contrast, CD80 expression was
similar (SF CD80 median, 7.5; range, 2.0 to 21.9; n = 15; PB
CD80 median, 15.2; range, 13.1 to 21.4; n = 10). Likewise,
CD86 and CD80 expression on cells from patient and control
PB (not shown) was comparable.
To achieve insight into the activation state of CD27+ switch
memory B cells, the latter cells from SF and PB were stained
with mAbs to CD25, CD69, and HLA-DR. Percentages of
CD69+ and CD25+ cells from SF were significantly higher
than those in PB (SF CD69 median, 12.9; range, 8.8 to 17.0;
n = 5; PB CD69 median, 2.5; range, 0.4 to 4.5; n = 5; P =
0.007; SF CD25 median, 1.5; range, 0.9 to 1.8; n = 5; PB
CD25 median, 0.4; range, 0.2 to 0.5; n = 5; P = 0.007),
whereas the expression of HLA-DR was similar in the two
compartments (SF HLA-DR median, 90.9; range, 74.2 to
92.9; n = 5; PB HLA-DR median, 81.8; range, 71.4 to 98; n =
5).
CD27- switch memory B cells
CCR5+, CCR8+, and CCR9+  cells were significantly
increased, whereas CCR6+ and CCR7+ cells were decreased
in SF versus patient PB (Figure 4C and Table 3). CXCR2+ and
CXCR3+ cells were significantly more numerous, whereas
CXCR5+ cells were less abundant in SF than in patient PB
cells (Figure 4D and Table 3). CXCR4 expression was similar
in SF and patient PB cells (not shown). Few CXCR1+ cells
were detected in SF and patient PB (not shown). Expression
of all CCR and CXCR was similar in control (data not shown)
and patient PB cells.
Finally, SF cells expressed significantly higher levels of CD86
than did patient PB cells (P = 0.0001) (Figure 4D). In contrast,
CD80 expression was similar in SF and patient PB (SF CD80
median, 3.3; range, 1.2 to 10.3; n = 15; PB CD80 median,
4.9; range, 3.8 to 6.1; n = 10). CD86 and CD80 expression in
patient and control PB (not shown) was comparable. The per-
Figure 2
Transitional B cells in synovial fluid (SF) and peripheral blood (PB) in juvenile idiopathic arthritis (JIA) patients Transitional B cells in synovial fluid (SF) and peripheral blood (PB) in juvenile idiopathic arthritis (JIA) patients.  Cells from SF and PB of JIA patients, 
as well as from control PB, were analyzed with flow cytometry by gating on CD3-, CD14-, CD16-, and CD56- cells (non-B cell lineage cells) followed 
by gating on CD19+ cells and then on CD24high, CD38high cells. Results are expressed in a box plot (left panel) as median percentage of positive 
cells, minimum and maximum value. *P < 0.01 (patient PB versus SF) and P = 0.05 (patient versus control PB). One representative dot-blot for SF 
(middle panel) and PB (right panel) is shown. Insets on the right side of the Figure show that gated CD24highand CD38high B cells express immu-
noglobulin M and immunoglobulin D (upper inset) and CD10 (lower inset).Available online http://arthritis-research.com/content/11/5/R150
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Figure 3
Plasma blasts and Ig-secreting cells in synovial fluid (SF), peripheral blood (PB), and synovial tissue from juvenile idiopathic arthritis (JIA) patients Plasma blasts and Ig-secreting cells in synovial fluid (SF), peripheral blood (PB), and synovial tissue from juvenile idiopathic arthritis (JIA) patients.  
(a) Cells from JIA SF and PB, as well as from control PB, were analyzed with flow-cytometry gating, first on CD3-, CD14-, CD16-, and CD56- cells 
(non-B cell lineage cells), and then on CD19+cells, and finally analyzed for CD27 and CD20 expression. Results are expressed in a box plot as 
median percentage of positive cells, minimum and maximum value. *P < 0.05. One representative dot-blot for SF (middle panel) and PB (right panel) 
is shown. (b) IgG, IgA, or IgM CD19+immunoglobulin-secreting cells (ISCs) were detected in SF and PB from four JIA patients with ELISPOT. 
Results are expressed as mean ISC ± SD. *P = 0.028. (c) Serial synovial tissue sections from three JIA patients were stained with anti-IgG, anti-IgA, 
or anti-IgM mAbs by using the peroxidase method (brown staining).Arthritis Research & Therapy    Vol 11 No 5    Corcione et al.
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centage of CD69+ cells was significantly higher in SF than in
PB (SF CD69 median, 11.3; range, 4.0 to 14.2; n = 5; PB
CD69 median, 0.4; range, 0.1 to 1.2; n = 5; P = 0.007). In
contrast, CD25+ and HLA-DR+ cells were significantly more
abundant in SF than in PB (SF CD25 median, 1.1; range, 0.6
to 2.1; n = 5; PB CD25 median, 0.1; range, 0.03 to 2.0; n =
5; SF DR median, 83.8; range, 58.7 to 96.9; n = 5; PB DR
median, 91.2; range, 82.9 to 97.1; n = 5).
Characterization of B-cell infiltrates in synovial tissue 
from JIA patients
In three JIA cases (one with oligoarticular persistent and two
with oligoarticular extended JIA), histologic analysis of synovial
tissue sections demonstrated the presence of lymphoid
aggregates with predominant perivascular distribution [6].
Clusters of CD20+ B cells (Figure 5A) and CD3+ T cells (not
shown) were detected within lymphoid aggregates, whereas
CD138+ plasma cells were found at the periphery of such
aggregates (Figure 5A and 5B). Consistent with a previous
study [6], these aggregates were not organized in follicle-like
structures, because they tested negative for the expression of
the follicular dendritic cell marker CD21 (Figure 5C).
CD27+ cells were detected both within and around lymphoid
aggregates, consistent with CD27 expression by memory B
cells and plasma blasts/plasma cells [23], as well as by mem-
ory T cells [24] (Figure 5D).
Discussion
In this study, CD27+ and CD27- switch memory B cells from
oligoarticular JIA patients were found to be significantly
enriched in SF compared with PB, whereas CD27+IgM+ B
cells were equally represented in the two compartments.
A previous study showed that CD27- switch memory B cells
from normal subjects and systemic lupus erythematosus (SLE)
patients had substantial levels of Ig mutations but lower than
conventional CD27+ switch memory B cells [18]. The former
B cells expanded in the peripheral blood from SLE patients,
and this expansion correlated with high disease activity and
high titers of disease-specific autoantibodies [18]. In contrast,
the frequency of CD27- switch memory B cells was reported
to be normal in the peripheral blood from adult RA patients
[18]. Accordingly, in our study, these cells were detected in
similar proportions in the peripheral blood of oligoarticular JIA
patients and controls.
CD27- switch memory B cells from both PB and SF of our
patients did not express the FcRH4 surface marker, as
reported in SLE patients [18]. FcRH4- CD27- switch memory
B cells may be more responsive to activation and may expand
more easily in autoimmune diseases than their CD27-,
FcRH4+ counterparts, because FcRH4 is a potent inhibitor of
B-cell signaling [25].
All patients tested had an articular disease relapse. No signif-
icant differences in the proportions of most SF or PB B-cell
subpopulations were detected in patients subdivided accord-
Table 2
Chemokine-receptor expression in synovial fluid and peripheral blood CD27+ switch memory B cells
Chemokine receptors Synovial fluida(n = 13) Peripheral blooda(n = 13) P valueb
CCR1 7.0 (2.0-18) 6.5 (3.3-8.5) ns
CCR2 6.7 (2.4-28) 5.8 (4.4-6.9) ns
CCR3 6.9 (2.0-27.3) 6.5 (5.2-7.7) ns
CCR4 6.6 (2.3-21.5) 5.3 (2.9-6.4) ns
CCR5 25.0 (5.5-45) 36.8 (27.8-69.7) 0.0003
CCR6 18.7 (8.0-45) 3.4 (1.6-5.3) 0.019
CCR7 22.6 (8.0-50) 65.1 (40.2-72.7) 0.001
CCR8 24.0 (8.3-50) 7.1 (5.8-10.6) 0.0002
CCR9 23.1 (6.1-76) 6.2 (4.9-8) 0.004
CXCR1 9.7 (4.0-27.0) 3.0 (1.2-4.1) 0.001
CXCR2 44.4 (21.8-55.7) 6.8 (3.4-10.0) 0.002
CXCR3 83.6 (68.0-92.3) 7.3 (6.2-13.5) 0.002
CXCR4 49.0 (37.3-63.6) 72.2 (35.8-85.3) ns
CXCR5 39.3 (20.7-66.0) 79.5 (70.0-83.5) 0.001
aResults represent median percentage of positive cells, as assessed with flow cytometry. Values in parentheses are minimum and maximum 
values. bP values were calculated by comparing the results of JIA SF and PB cell staining. ns = not significant.Available online http://arthritis-research.com/content/11/5/R150
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ing to ongoing treatment or disease subtype (i.e., persistent
versus extended oligoarticular JIA). The only exception was
represented by plasma blasts that were significantly more
numerous in SF from extended than from persistent oligoartic-
ular JIA patients.
Memory B cells migrate selectively to inflamed tissues [26,27].
To gain more insight into the mechanisms of CD27+ and
CD27- switch memory B cell recruitment to the inflamed joints,
we investigated their expression of a panel of chemokine
receptors. CCR5, CCR8, CCR9, CXCR2, and CXCR3 were
upregulated, whereas CCR6, CCR7, and CXCR5 were down-
regulated on both SF memory B-cell subsets versus their PB
counterparts. In contrast, CXCR1 was found to be upregu-
lated in SF CD27+ but not CD27- switch memory B cells,
although the mechanisms underlying such a difference are
unknown.
These findings suggest that CD27+ and CD27-- switch mem-
ory B cells from oligoarticular JIA patients share a common set
of chemokine receptors, likely mediating their attraction to the
affected joints, where the respective chemokine ligands [28]
are abundantly produced as a consequence of chronic inflam-
mation [29-31]. Unfortunately, the chemotactic functionality of
Figure 4
Chemokine receptor and CD86 expression on switch memory B cells from juvenile idiopathic arthritis (JIA) patients Chemokine receptor and CD86 expression on switch memory B cells from juvenile idiopathic arthritis (JIA) patients.  Cells from JIA synovial fluid (SF) 
and peripheral blood (PB) were analyzed with flow-cytometry gating first on CD3-, CD14-, CD16-, and CD56- cells (non-B cell lineage cells), then on 
CD19+cells, and subsequently on CD27+ or CD27- cells before being analyzed for individual chemokines-receptor expression. (a) CC chemokine 
receptor expression on SF and PB CD27+switch memory B cells. Results are expressed in a box plot as median percentage of positive cells, mini-
mum and maximum value. *** P = 0.0002; P = 0.0003. **P = 0.001; P = 0.004. *P = 0.019. (b) CXC chemokine receptor and CD86 expression on 
SF and PB CD27+switch memory B cells. Results are expressed in a box plot as median percentage of positive cells, minimum and maximum value. 
***P = 0.0001. **P = 0.001; P = 0.002. (c) CCR expression on SF and paired PB CD27- switch memory B cells. Results are expressed in a box plot 
as median percentage of positive cells, minimum and maximum value. ***P = 0.0001; P = 0.0003. **P = 0.0034; P = 0.0041. (d) CXCR and CD86 
expression on SF and paired PB CD27-switch memory B cells. Results are expressed in a box plot as median percentage of positive cells, minimum 
and maximum value. ***P = 0.0001; P = 0.0006. **P = 0.0011.Arthritis Research & Therapy    Vol 11 No 5    Corcione et al.
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the chemokine receptors upregulated in switch memory B
cells could not be investigated because of the paucity of the
latter cells in SF.
In adulthood, transitional B cells generated in the bone marrow
are released into the bloodstream and transported to the
spleen, where they develop into long-lived mature B cells
[20,32]. Here, we demonstrated that transitional B cells were
virtually absent from the synovial fluid of JIA patients, whereas
they were detected in paired blood samples and found to be
significantly increased in comparison with control blood. Sim-
ilar observations have been reported in patients with Sjögren
syndrome and SLE [33,34].
In principle, the increased frequency of transitional B cells in
peripheral blood from JIA patients as compared with that in
normal controls might result from dysfunctional bone marrow
production or altered recirculation. Studies performed in SLE
and Sjögren disease would favor the latter hypothesis [33,34].
Expansion of transitional B cells in blood from HIV-infected
and idiopathic CD4+ T lymphocytopenia patients has been
correlated with increased serum levels of interleukin-7 [35,36].
Whether a similar correlation applies also to our patients
remains to be established.
In this study, CD138+ plasma cells were detected in synovial
tissue at the periphery of lymphoid aggregates, lacking follicu-
Table 3
Chemokine-receptor expression in SF and PB CD27- switch memory B cells
Chemokine receptors Synovial fluida(n = 13) Peripheral blooda(n = 13) P valueb
CCR1 5.4 (2.0-30) 5.1 (4.7-5.9) ns
CCR2 5.7 (1.0-34) 5.2 (3.4-6.6) Ns
CCR3 7.1 (4.0-28.1) 6.5 (5.7-7.0) ns
CCR4 6.0 (2.3-19.7) 5.1 (3.9-5.9) ns
CCR5 16.1 (3.4-31.9) 2.1 (1.6-4.4) 0.0001
CCR6 6.3 (2.0-20) 36.8 (27.8-69.7) 0.0003
CCR7 21.3 (5.0-68) 65.1 (40.2-72.7) 0.0034
CCR8 11.5 (4.3-38) 4.9 (3.0-7.0) 0.025
CCR9 12.7 (6.1-35) 5.5 (4.9-9.3) 0.0041
CXCR1 4.2 (0.2-9.1) 1.5 (1-3.5) ns
CXCR2 18.2 (15.8-22.5) 4.7 (3.8-6.1) 0.0011
CXCR3 49.5 (41.8-78) 6.5 (4-12.3) 0.0011
CXCR4 43.1 (30.5-54.8) 67.5 (33.5-90.8) ns
CXCR5 31.6 (20-57.1) 78.4 (63.4-91) 0.0006
aResults represent median percentage of positive cells as assessed with flow cytometry. Values in parentheses are minimum and maximum values. 
bP values were calculated by comparing the results of JIA SF and PB cell staining. ns = not significant.
Figure 5
Histologic analysis of synovial tissue sections from juvenile idiopathic arthritis (JIA) patients Histologic analysis of synovial tissue sections from juvenile idiopathic arthritis (JIA) patients.   Serial synovial tissue sections from three JIA patients 
were stained with CD20 (a), CD138 (b), CD21 (c), and CD27 (d) mAbs by using the peroxidase method. CD20+ B cells cluster within lymphoid 
aggregates, whereas CD138+ plasma cells localize at the periphery of such aggregates. Staining for CD21, a follicular dendritic cell marker, is neg-
ative, consistent with the absence of follicular organization. CD27+ cells are found both inside and outside the lymphoid aggregates.A va ila b le  o n lin e http://arthritis-research.com/content/11/5/R150
Page 11 of 12
(page number not for citation purposes)
lar organization and containing CD20+, CD27+ memory B
cells admixed with T cells. Synovial tissue from oligoarticular
JIA patients with active, long-standing disease was previously
shown to be infiltrated with high numbers of plasma cells [37].
Accordingly, we found an enrichment for IgG-secreting
plasma blasts in SF and a large amount of IgG-producing B
cells in synovial tissue. The functional significance of these
findings remains to be established.
We finally showed that SF CD27+ and CD27- switch memory
B  c e l l s  w e r e  a c t i v a t e d ,  a s  a s s e s s e d  b y  t h e  e x p r e s s i o n  o f
CD69, and expressed high levels of the CD86, but not CD80,
costimulatory molecule. Resting B cells are poor antigen-pre-
senting cells because of the low surface expression of costim-
ulatory molecules. Upregulation of CD86 on synovial memory
B cells suggests that these cells can efficiently present anti-
gen to and activate T cells, contributing to the persistence of
chronic inflammation [38-40]. Increased frequency of B cells
expressing costimulatory molecules also was reported in other
human autoimmune diseases [41-44]. The dual role of synovial
B cells as antibody-producing and antigen-presenting cells
supports their important pathogenic role in JIA and provides a
rationale for a clinical trial with the anti-CD20 mAb rituximab
[12], which has already shown therapeutic efficacy in adult RA
patients [10,11].
Conclusions
This study demonstrates for the first time an expansion of
switch memory B cells and IgG-secreting plasma blasts in the
SF from oligoarticular JIA patients. These memory B cells
belonged to both the CD27+ and the CD27- subsets and
expressed CD86, suggesting their involvement in antigen
presentation to T cells. Analysis of chemokines-receptor
expression on CD27+ and CD27- switch memory B cells delin-
eated potential mechanisms for their recruitment to the
inflamed joints. The dual role of synovial B cells as antibody-
producing and antigen-presenting cells supports their patho-
genic role in JIA and provides a rationale for a clinical trial with
the anti-CD20 mAb rituximab.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ET and VP contributed equally to this work. AC designed and
supervised  in vitro studies, analyzed data, and wrote the
paper. FF performed in vitro experiments (cell separation, flow-
cytometric analysis). MG participated in the design of the
study. AG performed histologic studies. AP performed statis-
tical analysis. RG provided normal peripheral blood samples.
CG supervised histologic studies. AM helped to draft the man-
uscript. ET contributed to research design, reviewed data, and
wrote the paper. VP designed research, reviewed data, and
wrote the paper. All authors read and approved the final man-
uscript.
Acknowledgements
Andrea Gregorio was supported by Fondazione Italiana Lotta al Neurob-
lastoma; Francesca Ferlito was supported by Ricerca finalizzata ministe-
riale.
References
1. Krumrey-Langkammerer M, Hafner R: Evaluation of the ILAR cri-
teria for juvenile idiopathic arthritis.  J Rheumatol 2001,
28:2544-2547.
2. Ravelli A, Martini A: Juvenile idiopathic arthritis.  Lancet 2007,
369:767-778.
3. Choy EH, Panayi GS: Cytokine pathways and joint inflamma-
tion in rheumatoid arthritis.  N Engl J Med 2001, 344:907-916.
4. Goronzy JJ, Weyand CM: Rheumatoid arthritis.  Immunol Rev
2005, 204:55-73.
5. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S: Mechanisms
of disease: the molecular and cellular basis of joint destruc-
tion in rheumatoid arthritis.  Nat Clin Pract Rheumatol 2005,
1:102-110.
6. Gregorio A, Gambini C, Gerloni V, Parafioriti A, Sormani MP, Gre-
gorio S, De Marco G, Rossi F, Martini A, Gattorno M: Lymphoid
neogenesis in juvenile idiopathic arthritis correlates with ANA
positivity and plasma cells infiltration.  Rheumatology (Oxford)
2007, 46:308-313.
7. Kamphuis S, Kuis W, de Jager W, Teklenburg G, Massa M, Gor-
don G, Boerhof M, Rijkers GT, Uiterwaal CS, Otten HG, Sette A,
Albani S, Prakken BJ: Tolerogenic immune responses to novel
T-cell epitopes from heat-shock protein 60 in juvenile idio-
pathic arthritis.  Lancet 2005, 366:50-56.
8. Massa M, Mazzoli F, Pignatti P, De Benedetti F, Passalia M, Viola
S, Samodal R, La Cava A, Giannoni F, Ollier W, Martini A, Albani
S: Proinflammatory responses to self HLA epitopes are trig-
gered by molecular mimicry to Epstein-Barr virus proteins in
oligoarticular juvenile idiopathic arthritis.  Arthritis Rheum
2002, 46:2721-2729.
9. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A,
Gambini C, Mancardi GL, Uccelli A, Pistoia V: Recapitulation of
B cell differentiation in the central nervous system of patients
with multiple sclerosis.  Proc Natl Acad Sci USA 2004,
101:11064-11069.
10. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska
A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-
targeted therapy with rituximab in patients with rheumatoid
arthritis.  N Engl J Med 2004, 350:2572-2581.
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J,
Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li
NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group:
The efficacy and safety of rituximab in patients with active
rheumatoid arthritis despite methotrexate treatment: results
of a phase IIB randomized, double-blind, placebo-controlled,
dose-ranging trial.  Arthritis Rheum 2006, 54:1390-1400.
12. Kuek A, Hazleman BL, Gaston JH, Ostor AJ: Successful treat-
ment of refractory polyarticular juvenile idiopathic arthritis
with rituximab.  Rheumatology (Oxford) 2006, 45:1448-1449.
13. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L,
Martini A: Bone marrow-derived mesenchymal stem cells
induce both polyclonal expansion and differentiation of B cells
isolated from healthy donors and systemic lupus erythemato-
sus patients.  Stem Cells 2008, 26:562-569.
14. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J,
Capra JD: Analysis of somatic mutation in five B cell subsets of
human tonsil.  J Exp Med 1994, 180:329-339.
15. Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad J Jr, Miljkovic V,
Cattoretti G, Califano A, Dalla-Favera R: Transcriptional analysis
of the B cell germinal center reaction.  Proc Natl Acad Sci USA
2003, 100:2639-2644.
16. Klein U, Rajewsky K, Kuppers R: Human immunoglobulin
(Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell
surface antigen carry somatically mutated variable region
genes: CD27 as a general marker for somatically mutated
(memory) B cells.  J Exp Med 1998, 188:1679-1689.
17. Fecteau JF, Cote G, Neron S: A new memory CD27-IgG+ B cell
population in peripheral blood expressing VH genes with low
frequency of somatic mutation.  J Immunol 2006,
177:3728-3736.Arthritis Research & Therapy    Vol 11 No 5    Corcione et al.
Page 12 of 12
(page number not for citation purposes)
18. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J,
Lee EH, Milner EC, Sanz I: A new population of cells lacking
expression of CD27 represents a notable component of the B
cell memory compartment in systemic lupus erythematosus.  J
Immunol 2007, 178:6624-6633.
19. Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS,
Cooper MD: Expression of the immunoregulatory molecule
FcRH4 defines a distinctive tissue-based population of mem-
ory B cells.  J Exp Med 2005, 202:783-791.
20. Carsetti R, Rosado MM, Wardmann H: Peripheral development
of B cells in mouse and man.  Immunol Rev 2004, 197:179-191.
21. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C,
Looney RJ, Sanz I, Anolik JH: Novel human transitional B cell
populations revealed by B cell depletion therapy.  J Immunol
2009, 182:5982-5993.
22. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehling-
haus G, Berek C, Hiepe F, Manz R, Radbruch A, Dörner T: Gener-
ation of migratory antigen-specific plasma blasts and
mobilization of resident plasma cells in a secondary immune
response.  Blood 2005, 105:1614-1621.
23. Agematsu K, Hokibara S, Nagumo H, Komiyama A: CD27: a mem-
ory B-cell marker.  Immunol Today 2000, 21:204-206.
24. Borst J, Hendriks J, Xiao Y: CD27 and CD70 in T cell and B cell
activation.  Curr Opin Immunol 2005, 17:275-281.
25. Davis RS, Dennis G Jr, Odom MR, Gibson AW, Kimberly RP, Bur-
rows PD, Cooper MD: Fc receptor homologs: newest members
of a remarkably diverse Fc receptor gene family.  Immunol Rev
2002, 190:123-136.
26. Hansen A, Lipsky PE, Dorner T: B cells in Sjogren's syndrome:
indications for disturbed selection and differentiation in
ectopic lymphoid tissue.  Arthritis Res Ther 2007, 9:218.
27. Henneken M, Dorner T, Burmester GR, Berek C: Differential
expression of chemokine receptors on peripheral blood B
cells from patients with rheumatoid arthritis and systemic
lupus erythematosus.  Arthritis Res Ther 2005, 7:R1001-R1013.
28. Baggiolini M: Chemokines and leukocyte traffic.  Nature 1998,
392:565-568.
29. Barnes MG, Aronow BJ, Luyrink LK, Moroldo MB, Pavlidis P, Passo
MH, Grom AA, Hirsch R, Giannini EH, Colbert RA, Glass DN,
Thompson SD: Gene expression in juvenile arthritis and
spondyloarthropathy: pro-angiogenic ELR+ chemokine genes
relate to course of arthritis.  Rheumatology (Oxford) 2004,
43:973-979.
30. Aggarwal A, Agarwal S, Misra R: Chemokine and chemokine
receptor analysis reveals elevated interferon-inducible pro-
tein-10 (IP)-10/CXCL10 levels and increased number of
CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients
with enthesitis-related arthritis (ERA).  Clin Exp Immunol 2007,
148:515-519.
31. Pharoah DS, Varsani H, Tatham RW, Newton KR, de Jager W,
Prakken BJ, Klein N, Wedderburn LR: Expression of the inflam-
matory chemokines CCL5, CCL3 and CXCL10 in juvenile idio-
pathic arthritis, and demonstration of CCL5 production by an
atypical subset of CD8+ T cells.  Arthritis Res Ther 2006, 8:R50.
32. Chung JB, Silverman M, Monroe JG: Transitional B cells: step by
step towards immune competence.  Trends Immunol 2003,
24:343-349.
33. Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P,
Pennec YL, Saraux A, Youinou P: Identification of transitional
type II B cells in the salivary glands of patients with Sjogren's
syndrome.  Arthritis Rheum 2006, 54:2280-2288.
34. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH,
Warnatz K: A new CD21low B cell population in the peripheral
blood of patients with SLE.  Clin Immunol 2004, 113:161-171.
35. Malaspina A, Moir S, Chaitt DG, Rehm CA, Kottilil S, Falloon J,
Fauci AS: Idiopathic CD4+ T lymphocytopenia is associated
with increases in immature/transitional B cells and serum lev-
els of IL-7.  Blood 2007, 109:2086-2088.
36. Malaspina A, Moir S, Ho J, Wang W, Howell ML, O'Shea MA, Roby
GA, Rehm CA, Mican JM, Chun TW, Fauci AS: Appearance of
immature/transitional B cells in HIV-infected individuals with
advanced disease: correlation with increased IL-7.  Proc Natl
Acad Sci USA 2006, 103:2262-2267.
37. Kruithof E, Bossche V Van den, De Rycke L, Vandooren B, Joos R,
Canete JD, Tak PP, Boots AM, Veys EM, Baeten D: Distinct syn-
ovial immunopathologic characteristics of juvenile-onset
spondylarthritis and other forms of juvenile idiopathic arthritis.
Arthritis Rheum 2006, 54:2594-2604.
38. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker
DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA: Differential
up-regulation of the B7-1 and B7-2 costimulatory molecules
after Ig receptor engagement by antigen.  J Immunol 1994,
153:1990-1997.
39. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ: Compar-
ative analysis of B7-1 and B7-2 costimulatory ligands: expres-
sion and function.  J Exp Med 1994, 180:631-640.
40. Liu YJ, Barthelemy C, de Bouteiller O, Arpin C, Durand I,
Banchereau J: Memory B cells from human tonsils colonize
mucosal epithelium and directly present antigen to T cells by
rapid up-regulation of B7-1 and B7-2.  Immunity 1995,
2:239-248.
41. Ranheim EA, Kipps TJ: Elevated expression of CD80 (B7/BB1)
and other accessory molecules on synovial fluid mononuclear
cell subsets in rheumatoid arthritis.  Arthritis Rheum 1994,
37:1637-1646.
42. Genc K, Dona DL, Reder AT: Increased CD80(+) B cells in
active multiple sclerosis and reversal by interferon beta-1b
therapy.  J Clin Invest 1997, 99:2664-2671.
43. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM: T cell
activation in rheumatoid synovium is B cell dependent.  J
Immunol 2001, 167:4710-4718.
44. Corcione A, Aloisi F, Serafini B, Capello E, Mancardi GL, Pistoia V,
Uccelli A: B-cell differentiation in the CNS of patients with mul-
tiple sclerosis.  Autoimmun Rev 2005, 4:549-554.